louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05538273: Optimal Management of Urinary Catheter in Gyn Onc
Official title: Optimal Management and Timing of Removal of Urinary Catheter Following Pelvic Surgery by the Gynecologic Oncology Surgeon
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Urinary Retention
Keywords: urinary retention
postoperative
urinary complications
pelvic surgery
hysterectomy
gynecologic oncology
Lead sponsor: WellSpan Health
Sponsor class: OTHER
First posted: 2022-09-13
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients who meets the eligibility criteria, undergoing pelvic surgery by a gynecologic oncologist. Simple and radical procedures included.

Brief summary: This is a combined retrospective observational study that will collect data on urinary catheter removal of patients who underwent pelvic surgery by a gynecologic oncologist to assess timing safety and its implications in postoperative care.


Eligibility criteria: Inclusion Criteria:

* Age above 18
* female gender
* undergoing pelvic surgery for benign or malignant indications by a gynecologic oncologist

Exclusion Criteria:

* Age less than 18 years of age at the time of surgery
* pregnant
* individual is a prisoner

Primary outcomes:
measure: Urinary retention rate after urinary catheter removal postoperatively
timeFrame: 30 days after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: York
country: United States
facility: WellSpan York Hospital
state: Pennsylvania
Study officials:
References:
Clinical trial NCT06365073: A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax
Official title: A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Anthrax
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
First posted: 2024-04-15
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with severe anthrax

Brief summary: This study is a clinical, multi-center, retrospective, case-control study. Patients clinically diagnosed with severe anthrax who meet the inclusion and exclusion criteria will be included in this study for analysis. Respiratory, circulation, nerve and other vital signs of patients with severe anthrax during hospitalization were recorded, and clinical data such as blood routine, blood biochemistry, coagulation function, myocardial injury, therapeutic drug use, and survival time of patients were recorded, as well as the survival situation of patients 28 days and 90 days after discharge.


Eligibility criteria: Inclusion Criteria:

1. The typical bacilli with capsules were found in smear examination and culture of various secretions, excretions, blood and cerebrospinal fluid.
2. Multiple organ dysfunction (MODS) in brain, heart, liver, kidney, coagulation or more than one organ failure.

Exclusion Criteria:

There are other conditions that affect short-term survival.

Primary outcomes:
measure: mortality rates of severe anthrax
timeFrame: 28 days and 90 days
Secondary outcomes:
measure: incidence of complications
timeFrame: in hospital
measure: Peripheral blood biomarkers associated with 28-day and 90-day mortality
timeFrame: 28 days and 90 days
measure: the improvement in 28-day and 90-day mortality with treatment for severe anthrax
timeFrame: 28 days and 90 days
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
Study officials:
References:
Clinical trial NCT00573573: Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism
Official title: Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Hyperparathyroidism
Keywords: PRIMARY HYPERPARATHYROIDISM
PARATHYROID NEOPLASMS
SECONDARY HYPERPARATHYROIDISM
HYPOCALCEMIA
Lead sponsor: GAAD Medical Research Institute Inc.
Sponsor class: OTHER
First posted: 2007-12-14
Enrollment: 2
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A study to determine the possibility of using far infrared radiation to treat Hyperparathyroidism.

Detailed description: Overactive parathyroid glands secrete an excess of parathyroid hormones, resulting in increased levels of calcium in the blood stream, which can lead to weakening of the bones and to kidney stones.

We are postulating that the non-invasive energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to stop the over secretion of the parathyroid hormones and normalize the body's metabolic functions.

Eligibility criteria: Inclusion Criteria:

* Persons with parathyroid disease

Exclusion Criteria:

* None

Primary outcomes:
measure: The primary end point is to determine the therapeutic effects of far infrared radiation on Hyperparathyroidism.
timeFrame: 2 years
Secondary outcomes:
measure: Effect of far infrared radiation treatment on other immune deficiency diseases like thyroidism and diabetes
timeFrame: 2 years
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: The Centre for Incurable Diseases
state: Ontario
Study officials:
affiliation: GAAD Medical Research Institute Inc.
name: Ken Nedd, M.D.
role: STUDY_DIRECTOR
affiliation: GAAD Medical Research Institute Inc.
name: Kwasi Donyina, Ph.D.
role: STUDY_CHAIR
References:
Clinical trial NCT03460873: Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the Prostate
Official title: Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the Prostate
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Benign Prostatic Hyperplasia (BPH)
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2018-03-09
Enrollment: 432
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: tertiary hospital

Brief summary: Prognostic factor in the patients with benign prostatic hyperplasia (BPH) who undergo holmium laser enucleation of the prostate


Eligibility criteria: Inclusion Criteria:

* Male patient scheduled to undergo prostatectomy using holmium laser

Exclusion Criteria:

* Urethral stricture, large bladder diverticulum, bladder neck contracture

Primary outcomes:
measure: Comparison of IPSS(International Prostate Symptom Score) changes
timeFrame: pre-operation and post-operation (3month, 6month)
Secondary outcomes:
measure: changes of voided urine volume
timeFrame: pre-operation and post-operation (3month, 6month)
measure: changes of residual urine volume
timeFrame: pre-operation and post-operation (3month, 6month)
measure: Occurrence of adverse event
timeFrame: post-operation (3month, 6month)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center, Sungkyunkwan University School of Medicine
Study officials:
References:
Clinical trial NCT02812173: Postoperative Patient Comfort and Quality of Micturition in Suprapubic Tube vs. Transurethral Catheterization After RARP
Official title: Prospective, Randomized, Three-arm, Open Controlled Trial Comparing the Quality of Micturition and the Patient Comfort by Various Urinary Drainage After Robot-assisted Radical Prostatectomy (RARP)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prostate Cancer
Keywords: urinary drainage
urethral catheter
suprapubic tube
pain
discomfort
radical prostatectomy
robotic surgery
urinary infection
Lead sponsor: St. Antonius Hospital Gronau
Sponsor class: OTHER
First posted: 2016-06-24
Enrollment: 234
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine, whether the postoperative quality of micturition and continence can be improved depending on the urinary drainage catheter and retention after robot assisted radical prostatectomy. Another finding could be the study of the pain assessment of the patient, as well as the pain medication at the various derivatives. Further check whether infections and the presence of bacteriuria can be reduced or avoided by the form of urinary drainage.


Eligibility criteria: Inclusion Criteria:

* Minimum age of 18 Years
* Voluntarily agreement to participate in this study
* filled in and signed Informed Consent
* release of medical records for regulatory or research purposes
* clinically organ-confined prostate cancer
* recommended and planned robot-assisted radical prostatectomy

Exclusion Criteria:

* Participation in other interventional trials that could interfere with the present study
* International Prostate Symptom Score (IPPS) \> 18
* History of radiation or chemotherapy
* History of transurethral prostate resection
* unable to provide informed consent
* unwillingness to storage and forwarding of pseudonymous data

Primary outcomes:
measure: Urinary leakage measured by pad test in grams
timeFrame: within the day 2 or day 5 after the surgery for 24 hours
Secondary outcomes:
measure: Detection of postoperative pain related to urinary drainage by numeric rating scale (NRS)
timeFrame: once a day, first 7 days after the surgery
measure: Recording of complications
timeFrame: within the 4 weeks after surgery
measure: Urine status measured by flow cytometry
timeFrame: within the day 2 or day 5 after the surgery
measure: Residual urine measured by bladder scan in ml
timeFrame: 3 times within the day 2 or day 5 after the surgery
Other outcomes:
Locations:
city: Gronau
country: Germany
facility: Department of Urology, Pediatric Urology and Urologic Oncology, St. Antonius Hospital Gronau
Study officials:
affiliation: St. Antonius Hospital Gronau
name: Nina Harke, MD.
role: PRINCIPAL_INVESTIGATOR
affiliation: St. Antonius Hospital Gronau
name: Mustapha Addali, MD.
role: STUDY_CHAIR
References:
Clinical trial NCT01101373: Treatment of Severe Depressive Illness by Targeted Brain Surgery
Official title: Bilateral Anterior Capsulotomy For Intractable Depression
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Major Depressive Disorder
Keywords: Limbic surgery
Stereotactic surgery
Major Depressive Disorder: Treatment Refractory
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2010-04-09
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All subjects who received BAC for treatment resistant depression between 2000 and 2009

Brief summary: This study will report on the outcome of a clinical program, operational since 1998, that has used surgery targeting an emotional pathway in the brain in the treatment of severe depressive illness that has failed to respond to all other available interventions. Benefit from surgery was anticipated on the basis that the lesion (bilateral anterior capsulotomy) is a well established surgical target for treating severe treatment resistant depression.

Detailed description: Since 1998 bilateral anterior capsulotomy (BAC) has been available to patients in British Columbia Canada who have treatment refractory severe depressive illness. This study will report on the outcome of patients who have received this intervention. BAC is achieved by stereotactic radiofrequency lesioning. To date 8 patients have received BAC. For all patients there is follow-up data of at least 24 months. The purpose of this retrospective study is to report on the surgical protocol and to demonstrate the efficacy and safety of BAC in severe depression.

Eligibility criteria: Inclusion Criteria:

* Severe treatment resistant depression of at least 5 years duration
* older than 18 years

Exclusion Criteria:

* Comorbid organic mental disorder
* Delusional disorder
* Substance disorder
* Neurological disease
* Cluster B personality disorder

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: UBC Hospital, 2255 Wesbrook Mall
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Christopher Honey, MD
role: STUDY_DIRECTOR
affiliation: University of British Columbia
name: Judy Allen, MD
role: STUDY_DIRECTOR
affiliation: University of British Columbia
name: Robert Hewko, MD
role: STUDY_DIRECTOR
affiliation: University of British Columbia
name: Caroline Gosselin, MD
role: STUDY_DIRECTOR
affiliation: University of British Columbia
name: Nicolas Bogod, MD
role: STUDY_DIRECTOR
affiliation: University of British Columbia
name: Jeff Martzke, MD
role: STUDY_DIRECTOR
affiliation: University of British Columbia
name: Patricia Taylor
role: STUDY_DIRECTOR
References:
Clinical trial NCT04135573: The Relationship Between NK Cell and Graves' Disease
Official title: Mechanism of NK Cell Disfunction in Graves' Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Graves Disease
Keywords: Atuoimmune thyroid disease
Graves' disease
Natural killer cell
Lead sponsor: Shandong Provincial Hospital
Sponsor class: OTHER_GOV
First posted: 2019-10-22
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adults aged of 18 to 75 years old

Brief summary: Graves' disease (GD) is one of organ specific autoimmune diseases, the pathogenesis is not elucidated.Natural Killer (Natural Killer, NK) cells is a kind of important immune regulator, several abnormalities of NK cell function and number in GD patients have been described in the investigators' previous study. It is remain unclear whether the NK cell disfunction is a consequence of GD.Based on the investigators' previous study, the investigators plan to monitor NK cell function in participants in the whole course of disease, analyze the association with relevant factors, such as thyroid function, immune state or treatment,to find out influences of thyroid hormones and thyroid receptor antibody affecting the function of NK cell. The investigators will reveal whether the disfunction of NK cell secondary to GD abnormal thyroid function and/or immune disorders, and realize the mechanics.


Eligibility criteria: Inclusion Criteria:

* New GD patients without any treatment
* Aged of 18 to 75 years old

Exclusion Criteria:

* Pregnant or lactating woman;
* Known autoimmune disease;
* Receiving psychotropic or hormonal drugs;
* Taking drugs that affect the body's immune function;
* Obviously poor compliance.

Primary outcomes:
measure: The number and function of NK cells changes of hyperthyroidism
timeFrame: measured after 2 years of follow-up
Secondary outcomes:
measure: Changes in serum levels
timeFrame: measured after 2 years of follow-up
Other outcomes:
Locations:
city: Jinan
country: China
facility: Shandong Provincial Hospital
state: Shandong
Study officials:
affiliation: Shandong Provincial Hospital
name: Haiqing Zhang
role: STUDY_CHAIR
References:
Clinical trial NCT01620073: Home-Based Versus Partner-Friendly Clinic Testing to Enhance Male Partner HIV-1 Testing During Pregnancy
Official title: Home-Based Versus Partner-Friendly Clinic Testing to Enhance Male Partner HIV-1 Testing During Pregnancy: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Male Partner
HIV Counseling and Testing
Home Based
Pregnancy
Keywords: Male partner
HIV counseling and testing
Home based
Pregnancy
Lead sponsor: University of Washington
Sponsor class: OTHER
First posted: 2012-06-15
Enrollment: 488
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The investigators hypothesize that home based HIV counseling and testing can increase male partner uptake of HIV testing during pregnancy.

The investigators study aims through a randomized clinical trial to determine whether a home-based model (HBM) versus a partner-friendly clinic model (PFM) can increase male uptake of HIV counseling and testing during pregnancy.


Eligibility criteria: Inclusion Criteria:

* Pregnant women and their male partners

Exclusion Criteria:

* Non-pregnant, minors, inability to live in study area for 6 weeks

Primary outcomes:
measure: Number of Male Partners Counseled and Tested for HIV During Pregnancy
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Kisumu
country: Kenya
facility: Ahero Sub-District Hospital, Nyando, Kenya
state: Nyanza
city: Kisumu
country: Kenya
facility: Ahero Sub-District Hospital
state: Nyanza
Study officials:
affiliation: University of Washington
name: Alfred O Osoti, MBChB MMed
role: PRINCIPAL_INVESTIGATOR
References:
citation: Osoti AO, John-Stewart G, Kiarie JN, Barbra R, Kinuthia J, Krakowiak D, Farquhar C. Home-based HIV testing for men preferred over clinic-based testing by pregnant women and their male partners, a nested cross-sectional study. BMC Infect Dis. 2015 Jul 30;15:298. doi: 10.1186/s12879-015-1053-2.
citation: Osoti AO, John-Stewart G, Kiarie J, Richardson B, Kinuthia J, Krakowiak D, Farquhar C. Home visits during pregnancy enhance male partner HIV counselling and testing in Kenya: a randomized clinical trial. AIDS. 2014 Jan 2;28(1):95-103. doi: 10.1097/QAD.0000000000000023.
Clinical trial NCT02595073: Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Moderate to Severe Atopic Dermatitis.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Atopic Dermatitis
Lead sponsor: Taro Pharmaceuticals USA
Sponsor class: INDUSTRY
First posted: 2015-11-03
Enrollment: 124
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis

Detailed description: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis

Eligibility criteria: Inclusion Criteria:

- male and non-pregnant females, age 6 months or older, with a confirmed diagnosis of moderate to severe atopic dermatitis (AD)

Exclusion Criteria:

- Lacks stable diagnosis of atopic dermatitis or has been diagnosed with mild atopic dermatitis.

Primary outcomes:
measure: The Number of Patients in Each Treatment Group That Have Clinical Success
timeFrame: 28 days
Secondary outcomes:
measure: Change From Baseline in %BSA Affected at Day 28 ± 2
timeFrame: 28 days
Other outcomes:
Locations:
city: Hawthorne
country: United States
facility: Taro Pharmaceuticals USA Inc.
state: New York
Study officials:
affiliation: http://www.novumprs.com/contact
name: Novum Pharmaceutical Research Services
role: STUDY_CHAIR
References:
Clinical trial NCT01072331: Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus
Official title: Pharmacokinetic/Pharmacodynamic Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Keywords: insulin resistance
Lead sponsor: Mitsubishi Tanabe Pharma Corporation
Sponsor class: INDUSTRY
First posted: 2010-02-22
Enrollment: 99
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effect of MP-513 on 24-h glycemic control in patients with type 2 Diabetes for 4 weeks administration.


Eligibility criteria: Inclusion Criteria:

* Patients who are 20 - 75 years old
* Patients who are under dietary management and taking therapeutic exercise for diabetes over 8 weeks before administration of investigational drug
* Patients whose HbA1c is ≥6.5% and \<10.0%
* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 8 weeks before administration of investigational drug.

Exclusion Criteria:

* Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc)
* Patients who are accepting treatments of arrhythmias
* Patients with serious diabetic complications
* Patients who are the excessive alcohol addicts
* Patients with severe hepatic disorder or severe renal disorder.
* Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception

Primary outcomes:
measure: Change From Baseline in 2-h Postprandial Glucose (Breakfast, Lunch and Dinner)
timeFrame: 4 weeks
measure: Change From Baseline in Plasma Glucose Area Under the Curve (AUC) 0 to 2h (Breakfast, Lunch and Dinner)
timeFrame: 4 weeks
Secondary outcomes:
measure: Change From Baseline in 24-h Mean Glucose
timeFrame: 4 weeks
measure: Change From Baseline in Fasting Plasma Glucose
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Suita
country: Japan
state: Osaka
Study officials:
affiliation: Mitsubishi Tanabe Pharma Corporation
name: Kazuoki Kondo, MD
role: STUDY_DIRECTOR
affiliation: Mitsubishi Tanabe Pharma Corporation
name: Tadashi Yoshida, MD
role: STUDY_DIRECTOR
References:
citation: Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2012 Nov;14(11):1040-6. doi: 10.1111/j.1463-1326.2012.01662.x. Epub 2012 Jul 29.